DeepMed Research

Medac Gesellschaft für klinische Spezialpräparate m.b.H.

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient

Phase 1

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Methotrexate (Metoject® prefilled pen)

First Posted Date: 2013-06-07

Last Posted Date: 2015-03-17

Lead Sponsor: medac GmbH

Target Recruit Count: 105

Registration Number: NCT01871961

Locations: 🇺🇸
Rheumatology Arthitis & Rheumatic Care center, South Miami, Florida, United States

Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: methotrexate prefilled pen
Drug: methotrexate prefilled syringe

First Posted Date: 2013-02-15

Last Posted Date: 2013-07-15

Lead Sponsor: medac GmbH

Target Recruit Count: 120

Registration Number: NCT01793259

Locations: 🇩🇪
Kerckhoff Clinic, Bad Nauheim, Germany

Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukaemia

Interventions: Drug: PEG-rASNase
Drug: Oncaspar

First Posted Date: 2010-12-02

Last Posted Date: 2013-05-20

Lead Sponsor: medac GmbH

Target Recruit Count: 56

Registration Number: NCT01251809

Locations: 🇩🇪
Charité Campus Benjamin Franklin Hämatologie, Onkologie, Transfusionsmedizin Medizinische Klinik III, Berlin, Germany
🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany

and more 27 locations

Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Phase 2

Completed

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Treosulfan

First Posted Date: 2010-02-05

Last Posted Date: 2010-02-05

Lead Sponsor: medac GmbH

Target Recruit Count: 75

Registration Number: NCT01063660

Locations: 🇩🇪
University of Rostock, Rostock, Germany

Dose-range Finding Treosulfan-based Conditioning

Phase 1

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Treosulfan

First Posted Date: 2010-02-05

Last Posted Date: 2023-11-03

Lead Sponsor: medac GmbH

Target Recruit Count: 56

Registration Number: NCT01063647

Locations: 🇵🇱
Silesian Medical University, Katowice, Poland
🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇩🇪
Charité University Hospital Berlin, Berlin, Germany

and more 4 locations

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Treosulfan

First Posted Date: 2010-02-04

Last Posted Date: 2010-02-04

Lead Sponsor: medac GmbH

Target Recruit Count: 45

Registration Number: NCT01062490

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)

Phase 2

Completed

Conditions: Acute Lymphoid Leukemia

Interventions: Drug: recombinant asparaginase

First Posted Date: 2009-09-23

Last Posted Date: 2011-03-01

Lead Sponsor: medac GmbH

Target Recruit Count: 12

Registration Number: NCT00983138

Locations: 🇩🇪
University Hospital Erlangen, Erlangen, Germany
🇳🇱
Sophia Children's Hospital, Rotterdam, Netherlands
🇩🇪
University Hospital Bonn, Bonn, Germany

and more 14 locations

Urokinase Therapy in Patients With Diabetic Foot Syndrome

Phase 3

Terminated

Conditions: Diabetic Foot
Ischemia
Arterial Occlusive Disease

Interventions: Procedure: standard therapy
Drug: Urokinase

First Posted Date: 2009-01-15

Last Posted Date: 2015-03-13

Lead Sponsor: medac GmbH

Target Recruit Count: 5

Registration Number: NCT00823225

Locations: 🇩🇪
Franziskus Krankenhaus, Berlin, Germany
🇩🇪
Klinikum Dortmund Nord GmbH, Dortmund, Germany
🇩🇪
Klinikum Karlsbad Langensteinbach, Karlsbad, Germany

and more 3 locations

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Busulfan
Drug: Treosulfan

First Posted Date: 2009-01-14

Last Posted Date: 2020-07-30

Lead Sponsor: medac GmbH

Target Recruit Count: 570

Registration Number: NCT00822393

Locations: 🇮🇹
Ospedale Civile Pescara, Pescara, Italy
🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪
Klinikum Nürnberg, 5. Medizinische Klinik, Nürnberg, Germany

and more 30 locations

Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: recombinant asparaginase
Drug: asparaginase

First Posted Date: 2008-11-02

Last Posted Date: 2013-02-27

Lead Sponsor: medac GmbH

Target Recruit Count: 199

Registration Number: NCT00784017

Locations: 🇳🇱
Erasmus MC, Rotterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy